Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Juliette Palle"'
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Vascular endothelial growth factor A is known to play a central role in tumor angiogenesis. Several studies showed that VEGF-A is also an immunosuppressive factor. In tumor-bearing hosts, VEGF-A can modulate immune cells (DC, MDSC, TAM) to induce the
Externí odkaz:
https://doaj.org/article/25433d176a3140da9467a7ca2b111936
Autor:
Enrique Pérez-Cuadrado-Robles, Guillaume Perrod, Alexandre Lansier, Juliette Palle, Antoine Mariani, Christophe Cellier, Gabriel Rahmi
Publikováno v:
Endoscopy. 54:E633-E634
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c13347e8ebbca7cf9e0b9a35793fd334
https://doi.org/10.1055/a-1730-4200
https://doi.org/10.1055/a-1730-4200
Immunotherapy represents one of the most promising emerging therapies for the treatment of gastrointestinal (GI) cancers. As for targeted therapies, the results of the first trials have underlined the need for biomarkers to select patients who benefi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c548528760cf76713985f5b1ed8185d3
https://doi.org/10.1007/13905_2021_10
https://doi.org/10.1007/13905_2021_10
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Frontiers, 2021, 12, pp.616837. ⟨10.3389/fimmu.2021.616837⟩
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Frontiers, 2021, 12, pp.616837. ⟨10.3389/fimmu.2021.616837⟩
Frontiers in Immunology, Vol 12 (2021)
Vascular endothelial growth factor A is known to play a central role in tumor angiogenesis. Several studies showed that VEGF-A is also an immunosuppressive factor. In tumor-bearing hosts, VEGF-A can modulate immune cells (DC, MDSC, TAM) to induce the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb7c147f098bf6767d2e8732c6551698
https://pubmed.ncbi.nlm.nih.gov/33854498
https://pubmed.ncbi.nlm.nih.gov/33854498
Publikováno v:
Drugs. 80(4)
The discovery of human epidermal growth factor receptor 2 (HER2) overexpression in 15–20% of gastric adenocarcinomas has been a key advance in the global care of this disease. Validated by the ToGA trial in the first-line setting of advanced HER2-p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4befc05eb33593bc1439bb3babc7dfb6
https://pubmed.ncbi.nlm.nih.gov/32077003
https://pubmed.ncbi.nlm.nih.gov/32077003
Autor:
Céline Lepère, Karine Le Malicot, Juliette Palle, Lysiane Marthey, Simon Pernot, Olivier Dubreuil, Cedric Lecaille, Aziz Zaanan, Jean-Baptiste Bachet, Julien Taieb, Thomas Aparicio, David Tougeron
Publikováno v:
British Journal of Cancer
Background Triplet chemotherapy, with docetaxel-5FU-oxaliplatin (TEFOX), has yielded promising results in patients with advanced and operable gastric adenocarcinoma. This may prove useful in treating signet ring cell carcinoma (SRCC), which is known
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18499fdc77f352c662d4eae2e158d35e
https://doi.org/10.1038/s41416-018-0133-7
https://doi.org/10.1038/s41416-018-0133-7
Autor:
Juliette Palle, Sylvain Manfredi, Julien Taieb, Pascal Artru, Samy Louafi, Aziz Zaanan, David Tougeron, Astrid Pozet, Florence Leroy, Emilie Soularue
Publikováno v:
Targeted Oncology. 13:107-112
Trastuzumab with fluoropyrimidine and cisplatin is the standard first-line treatment in patients with HER2-positive advanced gastro-esophageal adenocarcinoma. However, there are no safety and efficacy data of trastuzumab with FOLFIRI. To evaluate saf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e41020b996e45a1ff87707e14db1a95
https://doi.org/10.1007/s11523-017-0531-4
https://doi.org/10.1007/s11523-017-0531-4
Autor:
Franck Bonnetain, Juliette Palle, David Sefrioui, Francesco Savinelli, Olivier Bouché, C. Rebischung, Aziz Zaanan, Olivier Dubreuil, Thierry Lecomte, Vincent Hautefeuille, Samy Louafi, Julien Taieb, Astrid Pozet, May Mabro, Nicolas Williet, David Tougeron, Matthieu Sarabi, Meher Ben Abdelghani, Emilie Soularue, Cedric Lecaille, Florence Leroy, Benoit Rousseau, Christophe Louvet, Sylvain Manfredi, Pascal Artru, Johann Dreanic, Ludovic Evesque, Jerome Martin-Babau
Publikováno v:
Oncotarget
Introduction Trastuzumab in combination with platinum-based chemotherapy is the standard first-line regimen in HER2-positive advanced gastric cancer. However, there are very few data concerning efficacy of continuing trastuzumab beyond first-line pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ada90a05ebdea6a49ccc3b2db8e63c76
https://pubmed.ncbi.nlm.nih.gov/29254172
https://pubmed.ncbi.nlm.nih.gov/29254172
Publikováno v:
The American journal of medicine. 129(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::519138c00d9a1dd64f494936f1cc4460
https://pubmed.ncbi.nlm.nih.gov/26231171
https://pubmed.ncbi.nlm.nih.gov/26231171
Autor:
Julien Taieb, Juliette Palle, Olivier Dubreuil, David Tougeron, Matthieu Sarabi, Christophe Louvet, Nicolas Williet, Aziz Zaanan, Sylvain Manfredi, Jerome Martin-Babau, Pascal Artru, Emilie Soularue, Johann Dreanic, Ludovic Evesque, Astrid Pozet, C. Rebischung, Thierry Lecomte, Florence Le Roy, Meher Ben Abdelghani, Vincent Hautefeuille
Publikováno v:
Journal of Clinical Oncology. 35:94-94
94 Background: Trastuzumab in combination with platinum-based chemotherapy is the standard first line regimen in HER2 positive advanced gastric cancer. However, there is no data concerning continuation of trastuzumab beyond first line progression. Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6e54a0800d4d905581c06360d09aea6
https://doi.org/10.1200/jco.2017.35.4_suppl.94
https://doi.org/10.1200/jco.2017.35.4_suppl.94